105 related articles for article (PubMed ID: 20162620)
1. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?
Lok AS
Hepatology; 2010 Apr; 51(4):1107-9. PubMed ID: 20162620
[No Abstract] [Full Text] [Related]
2. A call for attention and trials on hepatitis B e antigen-negative, alanine aminotransferase-normal chronic hepatitis B virus infection.
Zhao H; Miao R
Hepatology; 2009 Aug; 50(2):658; author reply 658-9. PubMed ID: 19585650
[No Abstract] [Full Text] [Related]
3. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL.
Dai CY; Chuang WL; Huang JF; Yu ML
Hepatology; 2009 Feb; 49(2):704-5; author reply 705-6. PubMed ID: 19177587
[No Abstract] [Full Text] [Related]
4. [Predictors for virologic response in management of chronic hepatitis B].
Lee JM; Ahn SH
Korean J Hepatol; 2010 Mar; 16(1):1-4. PubMed ID: 20375637
[No Abstract] [Full Text] [Related]
5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
6. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
7. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
8. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?
Nair S; Perrillo RP
Hepatology; 2001 Nov; 34(5):1021-6. PubMed ID: 11679974
[TBL] [Abstract][Full Text] [Related]
9. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
10. Changing landscape of antiviral resistance management in chronic hepatitis B.
Nguyen T; Locarnini S; Desmond P
J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
[No Abstract] [Full Text] [Related]
11. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis B with lamivudine.
Khokhar N; Gill ML; Alam AY
J Coll Physicians Surg Pak; 2005 Feb; 15(2):78-80. PubMed ID: 15730830
[TBL] [Abstract][Full Text] [Related]
13. [Lamivudine treatment consensus from relative experts in 2003].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
[No Abstract] [Full Text] [Related]
14. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
Chien RN; Liaw YF; Atkins M
Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for chronic hepatitis B: are we doing any good to patients?
Wong VW; Sung JJ
J Antimicrob Chemother; 2009 Aug; 64(2):223-6. PubMed ID: 19468026
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial results and treatment resistance with lamivudine in hepatitis B.
Wright TL
Semin Liver Dis; 2004; 24 Suppl 1():31-6. PubMed ID: 15192799
[TBL] [Abstract][Full Text] [Related]
18. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
20. [Role of ribavirin in the treatment of chronic hepatitis B].
Galban García E; Vega Sánchez H; Gra Oramas B; Rodríguez Pérez A; Doval Hernández MA; Haedo Castro D; Rolo F; Lorenzo Morejón I; Ramos Sánchez V
Gastroenterol Hepatol; 2000 Apr; 23(4):165-9. PubMed ID: 10863856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
